NIKKEI 225
28,930.37 -292.40 (-1.00%) HANG SENG
19,831.67 -90.78 (-0.46%) CRUDE OIL
88.02 -0.09 (-0.10%) GOLD FUTURES
1,780.50 +3.80 (+0.21%) DOW
33,980.32 -171.69 (-0.50%) BTC-GBP
19,476.80 -506.75 (-2.54%)
NVAX Jan 2023 70.000 call
| Previous close | 5.4000 |
| Open | 4.3000 |
| Bid | 4.0500 |
| Ask | 4.3000 |
| Strike | 70.00 |
| Expiry date | 2023-01-20 |
| Day's range | 4.0000 - 4.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.13k |
- Editor's pickYahoo Finance
U.S. to end purchase of COVID-19 vaccines as industry pivots to commercial market
Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.
- Zacks
Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose
Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.
- Motley Fool
Why Novavax Stock Eked Out a Gain Today
The coronavirus might not pose the threat it once was, and Novavax (NASDAQ: NVAX) can be considered a laggard in the Great COVID-19 Vaccine Race, but the stock certainly has plenty of believers. The more important of these two filings was with the U.S. Food and Drug Administration (FDA). Novavax's money product of the moment, its coronavirus vaccine Nuvaxovid, won emergency use authorization (EUA) from the American regulator last month.
